person · Reporting owner

SCHIFF ANDREW N

Disclosed activity across 7 companies

Tapewire entity: 38918
SEC CIK: 0001172252

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aclaris Therapeutics, Inc.ACRS · Entity 5041	Director	June 04, 2026	June 08, 2026
Elevation Oncology, Inc.ELEV · Entity 77243	10% owner	June 16, 2023	June 21, 2023
Monte Rosa Therapeutics, Inc.GLUE · Entity 4828	Director	June 11, 2026	June 12, 2026
Viracta Therapeutics, Inc.SNSS · Entity 85616	10% owner	July 15, 2019	July 15, 2019
Zosano Pharma CorpZSAN · Entity 12518	10% owner	December 02, 2019	December 06, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aclaris Therapeutics, Inc.

Report date June 04, 2026 · Filed June 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	25,540	Reported balance After 2026-06-05 transaction · row 1 1 source row Row 1 · 2026-06-05 · Exercise / conversion · Acquired 11,580 · Balance 25,540 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.71 · Expires 2036-06-03	Direct	42,350	Reported balance After 2026-06-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-04 · Grant · Acquired 42,350 · Balance 42,350 F3: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date. F4: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	10,987	Reported balance After 2026-06-04 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-06-04 · Grant · Acquired 10,987 · Balance 10,987 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date. F4: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-06-05 · Exercise / conversion · Disposed 11,580 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F6: The shares underlying these restricted stock units vested on June 5, 2026.
Common StockSEC Table I · non-derivative	IndirectBy Aisling Capital IV LP	434,455	Reported balance Holding disclosure · report date 2026-06-04 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 434,455 F2: The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F2: The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

F3: The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date.

F4: This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.

F5: The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date.

F6: The shares underlying these restricted stock units vested on June 5, 2026.

Elevation Oncology, Inc.

Report date June 16, 2023 · Filed June 21, 2023

Jointly reported with Aisling Capital IV, LP, Aisling Capital Partners IV LLC, Aisling Capital Partners IV, LP, ELMS STEVE

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.47 · Expires 2033-06-15	IndirectSee footnote	31,238	Reported balance After 2023-06-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-06-16 · Grant · Acquired 31,238 · Balance 31,238 F1: The stock option vests as to 100% of the total shares on the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date. F2: This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests as to 100% of the total shares on the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

F2: This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued.

Monte Rosa Therapeutics, Inc.

Report date June 11, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.10 · Expires 2036-06-11	Direct	25,800	Reported balance After 2026-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-11 · Grant · Acquired 25,800 · Balance 25,800 F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.

Viracta Therapeutics, Inc.

Report date July 15, 2019 · Filed July 15, 2019

Jointly reported with Aisling Capital IV, LP, Aisling Capital Partners IV LLC, Aisling Capital Partners IV, LP, ELMS STEVE

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	10,100,000	Reported balance After 2019-07-15 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2019-07-15 · Purchase · Acquired 2,500,000 · Balance 10,100,000 F1: Shares held by Aisling Capital IV, LP ("Aisling"). Aisling Capital Partners IV, LP ("Aisling GP"), is the general partner of Aisling. Aisling Capital Partners IV LLC ("Aisling Partners"), is the general partner of Aisling GP. The individual managing members ("the Aisling Managers"), of Aisling Partners are Andrew Schiff, M.D. and Steve Elms. By virtue of these relationships, Aisling GP, Aisling Partners and the Aisling Managers may be deemed to have voting and investment power over the shares held by Aisling. Each of the reporting persons, other than Aisling, disclaims beneficial ownership of the shares held by Aisling, except to the extent of any pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Shares held by Aisling Capital IV, LP ("Aisling"). Aisling Capital Partners IV, LP ("Aisling GP"), is the general partner of Aisling. Aisling Capital Partners IV LLC ("Aisling Partners"), is the general partner of Aisling GP. The individual managing members ("the Aisling Managers"), of Aisling Partners are Andrew Schiff, M.D. and Steve Elms. By virtue of these relationships, Aisling GP, Aisling Partners and the Aisling Managers may be deemed to have voting and investment power over the shares held by Aisling. Each of the reporting persons, other than Aisling, disclaims beneficial ownership of the shares held by Aisling, except to the extent of any pecuniary interest therein, if any.

Zosano Pharma Corp

Report date December 02, 2019 · Filed December 06, 2019

Jointly reported with Aisling Capital IV, LP, Aisling Capital Partners IV, LP, Aisling Capital Partners IV LLC, ELMS STEVE

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value of $0.0001SEC Table I · non-derivative	Direct	2,718,226	Reported balance After 2019-12-02 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2019-12-02 · Grant · Acquired 689,655 · Balance 2,718,226 F1: The securities are directly held by Aisling Capital IV, LP ("Aisling"), and may be deemed to be beneficially owned by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms.

Filing footnotes · ownership attribution and instrument terms

F1: The securities are directly held by Aisling Capital IV, LP ("Aisling"), and may be deemed to be beneficially owned by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Loxo Oncology, Inc.

Report date July 10, 2018 · Filed July 12, 2018

Jointly reported with AISLING CAPITAL III LP, Aisling Capital Partners III LP, Aisling Capital Partners III LLC, ELMS STEVE, Purcell Dennis J

Section 16 reporting ended · disclosed 2018-07-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,038,920	Reported balance After 2018-07-10 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-07-10 · Sale · Disposed 1,400,000 · Balance 2,038,920 F1: The securities are directly held by Aisling Capital III, LP ("Aisling"), and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer's Board of Directors. Dr. Joshua Bilenker, the Issuer's President and Chief Executive Officer, is a member of the Issuer's Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the "Investment Committee") of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling.

Filing footnotes · ownership attribution and instrument terms

F1: The securities are directly held by Aisling Capital III, LP ("Aisling"), and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer's Board of Directors. Dr. Joshua Bilenker, the Issuer's President and Chief Executive Officer, is a member of the Issuer's Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the "Investment Committee") of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling.

Zeltiq Aesthetics Inc

Report date April 28, 2017 · Filed May 01, 2017

Section 16 reporting ended · disclosed 2017-05-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-04-28 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2017-04-28 · Disposition to issuer · Disposed 13,137 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). F2: Pursuant to the terms of the Merger Agreement, out of the total of 13,137 shares held by the Reporting Person, (i) 11,587 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes (the "Merger Consideration"), and (ii) 1,550 shares, representing unvested restricted stock units, were converted into a corresponding award of restricted stock units with respect to ordinary shares of Allergan, on the same terms and conditions as were applicable under such restricted stock units, as adjusted based on an exchange ratio. F3: Includes 87 shares of Common Stock held by a trust for the benefit of Mr. Schiff's children.
Common StockSEC Table I · non-derivative	IndirectBy Aisling Capital III, L.P.	Reported balance After 2017-04-28 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2017-04-28 · Disposition to issuer · Disposed 1,597,742 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). F4: Pursuant to the terms of the Merger Agreement, these shares were cancelled and converted into the right to receive the Merger Consideration. F5: Represents shares of Common Stock directly held by Aisling Capital III, LP ("Aisling") and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III, LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Andrew Schiff is a member of the Board of Directors of Zeltiq Aesthetics, Inc.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.06 · Expires 2022-06-14	Direct	Reported balance After 2017-04-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-04-28 · Disposition to issuer · Disposed 1,589 · Balance 0 F6: This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option multiplied by the excess, if any, of the Merger Consideration over the exercise price of such option.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger").

F2: Pursuant to the terms of the Merger Agreement, out of the total of 13,137 shares held by the Reporting Person, (i) 11,587 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes (the "Merger Consideration"), and (ii) 1,550 shares, representing unvested restricted stock units, were converted into a corresponding award of restricted stock units with respect to ordinary shares of Allergan, on the same terms and conditions as were applicable under such restricted stock units, as adjusted based on an exchange ratio.

F3: Includes 87 shares of Common Stock held by a trust for the benefit of Mr. Schiff's children.

F4: Pursuant to the terms of the Merger Agreement, these shares were cancelled and converted into the right to receive the Merger Consideration.

F5: Represents shares of Common Stock directly held by Aisling Capital III, LP ("Aisling") and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III, LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Andrew Schiff is a member of the Board of Directors of Zeltiq Aesthetics, Inc.

F6: This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option multiplied by the excess, if any, of the Merger Consideration over the exercise price of such option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 04, 2020 Filed Jun 8, 2020 17:27 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantOption Grant (right to buy) · Derivative	16,500	$0.00 Strike: $1.41	$0.00	Disclosure SEC source: 0001209191-20-035029 · doc4.xml · derivative · entry 3 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2030-06-03 F3 · derivative.exercise_date: The shares subject this option will vest in twelve equal monthly installments commencing July 4, 2020, subject to Reporting Person's continuous service through each such date. Read SEC document
March 02, 2020 Filed Mar 4, 2020 16:28 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionRestricted stock units · Derivative	8,876	$0.00	$0.00	Disclosure SEC source: 0001209191-20-016090 · doc4.xml · derivative · entry 4 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,876 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest immediately. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest immediately. Read SEC document
March 02, 2020 Filed Mar 4, 2020 16:28 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted stock units · Derivative	8,876	$0.00	$0.00	Disclosure SEC source: 0001209191-20-016090 · doc4.xml · derivative · entry 3 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,876 Underlying: Common Stock · 8,876 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest immediately. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest immediately. Read SEC document
March 02, 2020 Filed Mar 4, 2020 16:28 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	Exercise / conversionCommon Stock	8,876	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-016090 · doc4.xml · nonDerivative · entry 1 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document
December 02, 2019 Filed Dec 6, 2019 10:23 UTC	Zosano Pharma Corp ZSAN · Entity 12518	GrantCommon Stock, par value of $0.0001	689,655	$1.45	$999,999.75	Disclosure SEC source: 0000899243-19-028646 · doc4.xml · nonDerivative · entry 1 Aisling Capital IV, LP · CIK 0001652910 · 10% owner Aisling Capital Partners IV, LP · CIK 0001737020 · 10% owner Aisling Capital Partners IV LLC · CIK 0001737019 · 10% owner ELMS STEVE · CIK 0001250195 · 10% owner SCHIFF ANDREW N · CIK 0001172252 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,718,226 F1 · ownership.direct: The securities are directly held by Aisling Capital IV, LP ("Aisling"), and may be deemed to be beneficially owned by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Read SEC document
July 15, 2019 Filed Jul 15, 2019 16:15 UTC	Viracta Therapeutics, Inc. SNSS · Entity 85616	PurchaseCommon Stock	2,500,000	$0.60	$1,500,000.00	Disclosure SEC source: 0000899243-19-019602 · doc4.xml · nonDerivative · entry 1 Aisling Capital IV, LP · CIK 0001652910 · 10% owner Aisling Capital Partners IV LLC · CIK 0001737019 · 10% owner Aisling Capital Partners IV, LP · CIK 0001737020 · 10% owner SCHIFF ANDREW N · CIK 0001172252 · 10% owner ELMS STEVE · CIK 0001250195 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 10,100,000 F1 · ownership.nature: Shares held by Aisling Capital IV, LP ("Aisling"). Aisling Capital Partners IV, LP ("Aisling GP"), is the general partner of Aisling. Aisling Capital Partners IV LLC ("Aisling Partners"), is the general partner of Aisling GP. The individual managing members ("the Aisling Managers"), of Aisling Partners are Andrew Schiff, M.D. and Steve Elms. By virtue of these relationships, Aisling GP, Aisling Partners and the Aisling Managers may be deemed to have voting and investment power over the shares held by Aisling. Each of the reporting persons, other than Aisling, disclaims beneficial ownership of the shares held by Aisling, except to the extent of any pecuniary interest therein, if any. Read SEC document
June 06, 2019 Filed Jun 10, 2019 16:49 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantRestricted Stock Units · Derivative	7,333	$0.00	$0.00	Disclosure SEC source: 0001209191-19-035829 · doc4.xml · derivative · entry 1 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,333 Underlying: Common Stock · 7,333 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · shares: This grant was made pursuant to the issuer's amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest on June 6, 2020, subject to the Reporting Person's continuous service with the issuer as of the vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest on June 6, 2020, subject to the Reporting Person's continuous service with the issuer as of the vesting date. Read SEC document
April 11, 2019 Filed Apr 12, 2019 16:15 UTC	Zosano Pharma Corp ZSAN · Entity 12518	GrantCommon Stock, par value of $0.0001	428,571	$3.50	$1,499,998.50	Disclosure SEC source: 0000899243-19-010594 · doc4.xml · nonDerivative · entry 1 Aisling Capital IV, LP · CIK 0001652910 · 10% owner Aisling Capital Partners IV, LP · CIK 0001737020 · 10% owner Aisling Capital Partners IV LLC · CIK 0001737019 · 10% owner ELMS STEVE · CIK 0001250195 · 10% owner SCHIFF ANDREW N · CIK 0001172252 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,028,571 F1 · ownership.direct: The securities are directly held by Aisling Capital IV, LP ("Aisling"), and may be deemed to be beneficially owned by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Read SEC document
July 10, 2018 Filed Jul 12, 2018 16:45 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	1,400,000	$179.43	$251,202,000.00	Disclosure SEC source: 0000899243-18-019810 · doc4.xml · nonDerivative · entry 1 AISLING CAPITAL III LP · CIK 0001444717 · 10% owner Aisling Capital Partners III LP · CIK 0001532634 · 10% owner Aisling Capital Partners III LLC · CIK 0001532635 · 10% owner ELMS STEVE · CIK 0001250195 · 10% owner SCHIFF ANDREW N · CIK 0001172252 · 10% owner Purcell Dennis J · CIK 0001297291 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,038,920 F1 · ownership.direct: The securities are directly held by Aisling Capital III, LP ("Aisling"), and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer's Board of Directors. Dr. Joshua Bilenker, the Issuer's President and Chief Executive Officer, is a member of the Issuer's Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the "Investment Committee") of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling. Read SEC document
June 07, 2018 Filed Jun 8, 2018 16:03 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (right to buy) · Derivative	8,000	$0.00 Strike: $18.35	$0.00	Disclosure SEC source: 0001209191-18-036653 · doc4.xml · derivative · entry 1 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2028-06-06 F1 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F2 · derivative.exercise_date: The shares underlying this option vest in twelve equal monthly installments through June 7, 2019, subject to the reporting person's continuous service as of such vesting date. Read SEC document
December 19, 2017 Filed Dec 20, 2017 16:31 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	250,000	$80.50	$20,125,000.00	Disclosure SEC source: 0000950142-17-002235 · es1701246_4-loxo.xml · nonDerivative · entry 1 AISLING CAPITAL III LP · CIK 0001444717 · 10% owner Aisling Capital Partners III LP · CIK 0001532634 · 10% owner Aisling Capital Partners III LLC · CIK 0001532635 · 10% owner ELMS STEVE · CIK 0001250195 · Director · 10% owner SCHIFF ANDREW N · CIK 0001172252 · 10% owner Purcell Dennis J · CIK 0001297291 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,438,920 F1 · ownership.direct: The securities are directly held by Aisling Capital III, LP ("Aisling"), and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer's Board of Directors. Dr. Joshua Bilenker, the Issuer's President and Chief Executive Officer, is a member of the Issuer's Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the "Investment Committee") of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling. Read SEC document
November 22, 2017 Filed Nov 27, 2017 19:29 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	500,000	$75.00	$37,500,000.00	Disclosure SEC source: 0000950142-17-002107 · es1701180_4-loxo.xml · nonDerivative · entry 1 AISLING CAPITAL III LP · CIK 0001444717 · 10% owner Aisling Capital Partners III LP · CIK 0001532634 · 10% owner Aisling Capital Partners III LLC · CIK 0001532635 · 10% owner ELMS STEVE · CIK 0001250195 · Director · 10% owner SCHIFF ANDREW N · CIK 0001172252 · 10% owner Purcell Dennis J · CIK 0001297291 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,688,920 F1 · ownership.direct: The securities are directly held by Aisling Capital III, LP ("Aisling"), and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer's Board of Directors. Dr. Joshua Bilenker, the Issuer's President and Chief Executive Officer, is a member of the Issuer's Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the "Investment Committee") of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling. Read SEC document
August 16, 2017 Filed Aug 16, 2017 16:45 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	PurchaseCommon Stock	108,601	$23.02	$2,499,995.02	Disclosure SEC source: 0001209191-17-049230 · doc4.xml · nonDerivative · entry 1 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aisling Capital IV LP Disclosed balance after: 634,455 F1 · ownership.nature: The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document
August 09, 2017 Filed Aug 14, 2017 08:21 UTC	Aclaris Therapeutics, Inc. ACRS · Entity 5041	GrantStock Option (right to buy) · Derivative	16,000	$0.00 Strike: $26.97	$0.00	Disclosure SEC source: 0001209191-17-048677 · doc4.xml · derivative · entry 1 SCHIFF ANDREW N · CIK 0001172252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2027-08-08 F1 · derivative.exercise_date: This option will vest and become exercisable in 36 equal monthly installments through August 9, 2020, subject to the reporting person's continuous service as of such vesting dates. Read SEC document
April 28, 2017 Filed May 1, 2017 13:34 UTC	Zeltiq Aesthetics Inc ZLTQ · Entity 176636	Disposition to issuerStock Option (Right to Buy) · Derivative	1,589	$0.00 Strike: $5.06	$0.00	Disclosure SEC source: 0000950142-17-000905 · es1700558_4-zeltiq.xml · derivative · entry 3 SCHIFF ANDREW N · CIK 0001172252 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,589 shares Expires 2022-06-14 F6 · derivative.exercise_date: This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option multiplied by the excess, if any, of the Merger Consideration over the exercise price of such option. Read SEC document
April 28, 2017 Filed May 1, 2017 13:34 UTC	Zeltiq Aesthetics Inc ZLTQ · Entity 176636	Disposition to issuerCommon Stock	1,597,742	Not disclosed	Not disclosed	Disclosure SEC source: 0000950142-17-000905 · es1700558_4-zeltiq.xml · nonDerivative · entry 2 SCHIFF ANDREW N · CIK 0001172252 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Aisling Capital III, L.P. Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). F4 · kind: Pursuant to the terms of the Merger Agreement, these shares were cancelled and converted into the right to receive the Merger Consideration. F1 · price: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). F4 · price: Pursuant to the terms of the Merger Agreement, these shares were cancelled and converted into the right to receive the Merger Consideration. F5 · ownership.nature: Represents shares of Common Stock directly held by Aisling Capital III, LP ("Aisling") and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III, LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Andrew Schiff is a member of the Board of Directors of Zeltiq Aesthetics, Inc. Read SEC document
April 28, 2017 Filed May 1, 2017 13:34 UTC	Zeltiq Aesthetics Inc ZLTQ · Entity 176636	Disposition to issuerCommon Stock	13,137	Not disclosed	Not disclosed	Disclosure SEC source: 0000950142-17-000905 · es1700558_4-zeltiq.xml · nonDerivative · entry 1 SCHIFF ANDREW N · CIK 0001172252 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). F2 · kind: Pursuant to the terms of the Merger Agreement, out of the total of 13,137 shares held by the Reporting Person, (i) 11,587 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes (the "Merger Consideration"), and (ii) 1,550 shares, representing unvested restricted stock units, were converted into a corresponding award of restricted stock units with respect to ordinary shares of Allergan, on the same terms and conditions as were applicable under such restricted stock units, as adjusted based on an exchange ratio. F1 · price: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). F2 · price: Pursuant to the terms of the Merger Agreement, out of the total of 13,137 shares held by the Reporting Person, (i) 11,587 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes (the "Merger Consideration"), and (ii) 1,550 shares, representing unvested restricted stock units, were converted into a corresponding award of restricted stock units with respect to ordinary shares of Allergan, on the same terms and conditions as were applicable under such restricted stock units, as adjusted based on an exchange ratio. F3 · ownership.direct: Includes 87 shares of Common Stock held by a trust for the benefit of Mr. Schiff's children. Read SEC document
January 10, 2017 Filed Jan 12, 2017 17:17 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	PurchaseCommon Stock	160,000	$31.00	$4,960,000.00	Disclosure SEC source: 0000950142-17-000108 · es1700164_4-loxo.xml · nonDerivative · entry 1 AISLING CAPITAL III LP · CIK 0001444717 · 10% owner Aisling Capital Partners III LP · CIK 0001532634 · 10% owner Aisling Capital Partners III LLC · CIK 0001532635 · 10% owner ELMS STEVE · CIK 0001250195 · Director · 10% owner SCHIFF ANDREW N · CIK 0001172252 · 10% owner Purcell Dennis J · CIK 0001297291 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,188,920 F1 · ownership.direct: The securities are directly held by Aisling Capital III, LP ("Aisling"), and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer's Board of Directors. Dr. Joshua Bilenker, the Issuer's President and Chief Executive Officer, is a member of the Issuer's Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the "Investment Committee") of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.